38th week of 2010 patent applcation highlights part 47 |
Patent application number | Title | Published |
20100240563 | Fast drying ampholytic polymers for cleaning compositions - The claims encompass hard surface cleaner and hard surface treatment compositions containing particular ampholytic polymers which impart not only good residual cleaning properties but in particular give fast drying properties to the cleaning compositions. The polymers are for example terpolymers formed from diallydialkyammonium chloride, anionic monomers and N,N di-C | 2010-09-23 |
20100240564 | FORMULATIONS OF CARBOXYLIC ACID DIESTERS USEFUL FOR TREATING/CLEANING TEXTILE AND OTHER MATERIALS - Carboxylic acid diesters are employed for treating, in particular for cleaning textile and other materials, and more particularly for removing paint stains from textile fibers to improve the cleaning thereof; the subject formulations contain at least one dicarboxylic acid diester having the formula (I), R | 2010-09-23 |
20100240565 | Composition - Disclosed is use of an aqueous composition comprising a bleach and an optical brightener as a pre-treatment composition in a laundry/fabric washing operation, as well as compositions and dispensing devices comprising the pre-treatment composition. | 2010-09-23 |
20100240566 | Washing or Cleaning Agents with Amidine Compounds and/or Amidinium Bicarbonates - Washing and cleaning agents containing a specific amidine compound and/or specific amidinium bicarbonate. These washing or cleaning agents enable an improved removal of contaminants due to pigment contamination and fat and oil soiling. Use of special amidine compounds and amidinium bicarbonate in a washing solvent is also described, which enables carbon dioxide from ambient air to bind in the washing solvent. | 2010-09-23 |
20100240567 | TREATMENT/CLEANING OF TEXTILE MATERIALS UTILIZING FORMULATIONS OF CARBOXYLIC ACID DIESTERS - Carboxylic acid diesters are employed for treating, in particular for cleaning textile materials, and more particularly for removing paint stains from textile fibers to improve the cleaning thereof; the subject dicarboxylic acid diesters have the formula (I), R | 2010-09-23 |
20100240568 | Textile Pretreatment Agent having Gel Comprising Active Agent - Textile pretreatment agent comprising at least two water-insoluble layers connected to each other, a gel comprising active agent being disposed there between in a manner sealed against water vapor. The gel comprising active agent bonds more strongly to a textile web material than to the water-insoluble layers and can thus be applied to a stain easily and without undesired skin contact. | 2010-09-23 |
20100240569 | STRUCTURED FLUID DETERGENT COMPOSITIONS COMPRISING DIBENZYLIDENE SORBITOL ACETAL DERIVATIVES - Fluid detergent compositions comprising from about 0.01% to about 1% by weight of an external structurant comprising dibenzylidene sorbitol acetal derivatives for providing desired rheological benefits such as product thickening, shear thinning behavior, as well as particle suspension capabilities. | 2010-09-23 |
20100240570 | Composition for Use in the Laundering or Treatment of Fabrics, and a Process for Making the Composition - The present invention relates to an auxiliary composition, for use in the laundering or treatment of fabrics, comprising an admix of (i) clay and (ii) a silicone in an emulsified form. | 2010-09-23 |
20100240571 | STRUCTURED FLUID DETERGENT COMPOSITIONS COMPRISING DIBENZYLIDENE POLYOL ACETAL DERIVATIVES AND DETERSIVE ENZYMES - Fluid detergent compositions comprising an external structurant comprising dibenzylidene polyol acetal derivatives for providing desired rheological benefits such as product thickening, shear thinning behavior, as well as particle suspension capabilities, and a detersive enzyme such as lipase. | 2010-09-23 |
20100240572 | SPRAY-BASED DEGREASING FLUID - Disclosed is a composition for degreasing surfaces comprising about 75 to about 99.9% by volume parachlorobenzotrifluoride and about 0.1 to about 25% by volume of an organic modifier selected from the group consisting of odorless mineral spirits, an alkane from C1 to C8, acetone, an alcohol from C1 to C8, benzene, xylene, toluene, Stoddard's solvent, t-butyl acetate, a glycol, isoparaffin, and dimethylene carbonate. Additionally, it relates to a degreasing fluid comprising parachlorobenzotrifluoride to be applied using a spray application. | 2010-09-23 |
20100240573 | SPRAY-BASED DEGREASING FLUID - Disclosed is a composition for degreasing surfaces comprising about 97.4 to 100% by volume parachlorobenzotrifluoride and 0 to about 2.6% by volume of a masking agent. Further provided is a method for degreasing surfaces comprising the above composition and providing a spray application means for applying the composition. | 2010-09-23 |
20100240574 | Heyl as a Therapeutic Target and a Diagnostic Marker for Neoplasia and Uses Therefor - The invention generally features compositions and methods that are useful for treating or diagnosing a neoplasia, in particular breast neoplasia. The invention is based in part on the observation that the basic helix loop helix transcription factor HEYL was found to be overexpressed in breast cancer cells. Accordingly, the invention provides therapeutic compositions and methods for altering the levels and expression of HEYL of the invention, thereby treating a neoplasia, as well as compositions and methods for diagnosing a neoplasia. | 2010-09-23 |
20100240575 | ANTI-OBESE IMMUNOGENIC HYBRID POLYPEPTIDES AND ANTI-OBESE VACCINE COMPOSITION COMPRISING THE SAME - Disclosed is an immunogenic hybrid polypeptide comprising a mimetic peptide of a B cell epitope of apolipoprotein B-100 and helper T cell epitope, the mimetic peptide being fused at its C-terminus to an N-terminus of the helper T cell epitope. Also disclosed is a vaccine composition for preventing or treating obesity comprising the polypeptide. | 2010-09-23 |
20100240576 | ANTICONVULSANT COMBINATION THERAPY - The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures. | 2010-09-23 |
20100240577 | Bacteriocins and Novel Bacterial Strains - Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry. | 2010-09-23 |
20100240578 | ANTI-H5N1 INFLUENZA ACTIVITY OF THE ANTIVIRAL PROTEIN CYANOVIRIN - The invention is directed to a method of inhibiting prophylactically or therapeutically an H5N1 viral infection in a host, which method comprises administering to the host an anti-viral effective amount of an antiviral protein comprising the amino acid sequence of SEQ ID NO: 1 or a nucleic acid encoding the antiviral protein, as well as antiviral portions, variants, and conjugates thereof. | 2010-09-23 |
20100240579 | DETECTION OF CELL SURFACE BINDING MOLECULES USING A PHAGE DISPLAY BLOCKING ASSAY - The present invention relates to the use of a phage blocking assay to determine unknown binding molecule present on or in the surface of a cell, a non-infectious moiety, a bacteria, a virus, or another pathogen. In particular embodiments, the invention relates to the identification of unknown receptors on a cell or virus involved in infection. Further, it relates to the use of said binding molecules, for example virus binding molecules or cellular receptors and binding members with binding specificity to said binding molecules, for example antibodies, in methods of therapy. | 2010-09-23 |
20100240580 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF - The invention relates to azoloarine derivatives of formula I | 2010-09-23 |
20100240581 | SELECTIVE PROTEASOME INHIBITORS FOR TREATING DIABETES - Methods of modulating chronic low-grade inflammation are provided. More particularly, methods of treating diabetes, such as for example, type-2 diabetes mellitus, in a mammal by administering an effective amount of a selective proteasome inhibitor are provided. Also provided are unit dosage forms of such inhibitors. | 2010-09-23 |
20100240582 | Peptides and related molecules that modulate nerve growth factor activity - The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided. | 2010-09-23 |
20100240583 | SOLUBLE PROTEIN AND UTILIZATION OF THE SAME - The present invention relates to a method for screening a medicine using a protein, and a compound obtained by the screening method. | 2010-09-23 |
20100240584 | Nematode-extracted serine protease inhibitors and anticoagulant proteins - Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA, expression systems. | 2010-09-23 |
20100240585 | IN VIVO CELL SURFACE ENGINEERING - The present invention provides methods and compositions for the in vivo engineering of cell surfaces, such as tumor cell surfaces, with one or more immune co-stimulatory polypeptides. The methods, compositions and engineered cells are useful, for example, to stimulate an immune response against the cells. When the engineered cell surfaces are tumor cell surfaces, the methods, compositions and engineered cells are useful for improving a patient's immune response against the cancer and for reducing tumor size and inhibiting tumor growth. | 2010-09-23 |
20100240586 | PEG MODIFIED EXENDIN OR EXENDIN ANALOG AND COMPOSITIONS AND USE THEREOF - Exendins or exendin analogs modified by one or more PEG derivatives that may be linked to one or more amino acids of the exendins or exendin analogs are provided. The PEG derivatives may have branched structure set forth in any one of formulas I-IV. Compositions including the PEG derivative modified exendin or exendin analog, methods of making or administering the modified exendin or exendin analog, and various uses thereof are also provided. | 2010-09-23 |
20100240587 | STABLE FORMULATIONS OF AMYLIN AND ITS ANALOGUES - The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and an anionic surfactant, and methods for treatment of hyperglycemia. | 2010-09-23 |
20100240588 | COMPOUND FOR USE IN THE TREATMENT OF PERIPHERAL NEUROPATHIES - The present invention relates to a compound of the following formula (I): | 2010-09-23 |
20100240589 | DIASTEREOMERIC PEPTIDES USEFUL AS INHIBITORS OF MEMBRANE PROTEIN ASSEMBLY - The present invention relates to membrane binding diastereomeric peptides comprising amino acid sequences corresponding to a fragment of a transmembrane proteins, wherein at least two amino acid residues of the diastereomeric peptides being in a D-isomer configuration. The diastereomeric peptides are useful in inhibiting fusion membrane protein events, including specifically viral replication and transmission. | 2010-09-23 |
20100240590 | PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1 - The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz | 2010-09-23 |
20100240591 | TPP II INHIBITORS FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES AND TRANSPLANT REJECTION - TPP II (tripeptidyl peptidase II) inhibitors are useful in the treatment of autoimmune and/or inflammatory diseases, for example Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Sjögrens Syndrome, Diabetes Mellitus Type I or II, Psoriasis, Eczema, Ulcerous Colitis, and Chron's Disease, or transplant rejection. Suitable compounds comprise tripeptide compounds of general formula R | 2010-09-23 |
20100240592 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY - Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining Symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as | 2010-09-23 |
20100240593 | STRONTIUM-APATITE CEMENT PREPARATION CEMENTS FORMED THEREFROM, AND USE THEREOF - Calcium-strontium-hydroxyphosphate (strontium-apatite-) cement preparations are described, comprising a powder mixture, which contains molar quantities of the components calcium (Ca), strontium (Sr) and phosphate (P) in the mixture in the ranges 1.002010-09-23 | |
20100240594 | TARGETED DELIVERY OF CHEMOTHERAPEUTIC AGENTS - The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of chemotherapeutic agents. | 2010-09-23 |
20100240595 | Improved Antitumoral Treatments - The present invention relates to combinations of Aplidine with Gemcitabine, and the use of these combinations in the treatment of cancer. | 2010-09-23 |
20100240596 | REPAIR OF RUPTURED MEMBRANE BY INJECTION OF NATURALLY OCCURRING PROTEIN IN AMNIOTIC FLUID SAC - The present invention provides compositions and methods for use in treatment of premature rupture of membrane. The compositions of the invention include a therapeutic amount of an avian thick egg white composition. Preferably, the compositions include the purified thick egg white protein, ovomucin. The methods of the invention involve injecting an effective amount of the compositions into the prematurely ruptured amniotic sac of a patient in order to seal the rupture. | 2010-09-23 |
20100240597 | METHODS OF DELIVERY OF MOLECULES TO CELLS USING A RICIN SUBUNIT AND COMPOSITIONS RELATING TO SAME - A method of preparing molecules of interest for delivery to eukaryotic cells is shown, wherein a ricin B chain subunit not having a ribosome inactivating subunit and retaining lectin activity is modified by modifying the first cysteine residue to be absent or substituted with an amino acid other than cysteine, or removing a protease sensitive site at the N-terminal of the subunit, or adding an endoplasmic reticulum retrieval signal, and operatively associating the subunit with a molecule of interest. Methods of operatively associating the subunit and molecule of interest include chemical conjugation at primary amines, conjugation with N-glycans of the subunit, a disulfide bond, and assembly of immunoglobulin domains. The invention provides for operatively associating multiple molecules of interest with a ricin B chain subunit, and delivery into targeted cells, cell components, and combination of cells. | 2010-09-23 |
20100240598 | PEPTIDES AND PEPTIDE MIMETICS TO INHIBIT THE ONSET AND/OR PROGRESSION OF FIBROTIC AND/OR PRE-FIBROTIC PATHOLOGIES - This invention provides methods of inhibiting the onset or progression of a fibrotic disease (or pre-fibrotic pathology) in a mammal. The method involves administering oen or more peptides (e.g., class A amphipathic helical peptides, G* peptides, etc.) as described herein to a mammal in need thereof, in an amount effective to inhibit the onset and/or progression of the fibrotic disease (or pre-fibrotic condition) in the mammal. In certain embodiments the fibrotic disease is selected from the group consisting of retroperitoneal fibrosis (RPF), hepatic fibrosis and/or chirrhosis, renal fibrosis, and pancreatic fibrosis | 2010-09-23 |
20100240599 | ANTIOXIDANT CONSTITUENTS - An object of the present invention is to provide an antioxidant composition that is effective in the living body against active oxygen species produced in the body. The present invention provides an antioxidant composition having the effect of suppressing three active oxygen species, i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite radicals, with respect to active oxygen species produced in the body, the antioxidant composition comprising a mixture in which at least 20 mg of vitamin C (L-ascorbic acid or sodium L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of caffeic acid analogue compound(s), at least 10 mg of polyphenyol compound(s) or at least 1.5 mg of carotenoid compound(s) as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof obtained from animal extract as an agent for scavenging hypochlorite active oxygen. | 2010-09-23 |
20100240600 | Anti-Norovirus Agent and Composition Containing the Same - Provided is an anti-norovirus agent that has high norovirus-inactivating activity and is safe for the human body, and an anti-norovirus composition that contains the anti-norovirus agent and is useful for disinfection and infection control against the norovirus. The anti-norovirus agent includes, as an active ingredient, an extract from a plant of the genus | 2010-09-23 |
20100240601 | Coordination Complexes, Pharmaceutical Solutions Comprising Coordination Complexes, and Methods of Treating Patients - A coordination complex having a physiologically acceptable pK | 2010-09-23 |
20100240602 | METHODS AND COMPOSITIONS FOR OPTIMIZING BLOOD AND TISSUE STABILITY OF CAMPTOTHECIN AND OTHER ALBUMIN-BINDING THERAPEUTIC COMPOUNDS - The present invention provides methods and formulations for optimizing the anti-cancer and anti-HIV activities of a camptothecin drug, including camptothecin and its related analogs including 9-aminocamptothecin and 9-nitrocamptothecin. The invention involves methodologies and formulations that limit human serum albumin-mediated reduction of the anti-cancer and anti-HIV effects of the camptothecins, and the methods and formulations provide combination therapies in which binding of the camptothecin agent to human serum albumin can be modulated by the administration of a competing agent such as ibuprofen, clofibrate or clofibric acid that also binds human serum albumin. Reduced camptothecin drug binding to human serum albumin can result in elevated camptothecin free drug levels and thus improve the effectiveness of treatment regimens involving these drugs. Further agents such as methotrexate and AZT can also be used in cancer and HIV-positive patients employing camptothecin drugs. | 2010-09-23 |
20100240603 | EXPRESSION INHIBITOR OF NUCLEAR TRANSCRIPTION FACTOR AP-1 AND PHARMACEUTICALS AND PRODUCTS USING THE SAME - An expression inhibitor of a nuclear transcription factor AP-1 is provided that is excellent in safety and activity of inhibiting the expression of a nuclear transcription factor AP-1. The AP-1 expression inhibitor of the present invention is characterized by containing chamaemeloside. In the present invention, chamaemeloside may be contained as an extract of Roman chamomile or German chamomile. The chamaemeloside is contained in Roman chamomile or German chamomile. Conventionally, Roman chamomile and German chamomile have been used as cosmetic materials and herb teas and have no problems in safety. An extract of Roman chamomile or German chamomile and chamaemeloside inhibit the expression of the AP-1 at the gene level (see FIG. | 2010-09-23 |
20100240604 | PROTECTED NUCLEOTIDE ANALOGS - Disclosed herein are nucleotide analogs with protected phosphates, methods of synthesizing nucleotide analogs with protected phosphates and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with protected phosphates. | 2010-09-23 |
20100240605 | NOVEL IMMUNOTHERAPY STRATEGY - The present invention relates to polyacetal-carboxylic acids, more in particular chlorite-oxidized oxyamylose (COAM) for use as a medicine, more in particular for the treatment or prevention of cancer and auto-immune disorders or relates to the use of polyacetal-carboxylic acids for the manufacture of a medicament for the prevention or treatment of cancer or auto-immune disorders. The invention provides also pharmaceutical compositions comprising said polyacetal-carboxylic acids and method of preventing or treating cancer and auto-immune disorders. | 2010-09-23 |
20100240606 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE - The invention is related to association products of xanthates and cyclodextrins, pharmaceutical formulations made therefrom, and medicaments containing these formulations for treating Alzheimer's, viral, tumor, cardiovascular, and autoimmune diseases such as rheumatism, multiple sclerosis, alopecia areata, lupus erythematosus, stroke, lung edema, or for use as radio-protectors. The association products contain a xanthate of general formula I | 2010-09-23 |
20100240607 | Dextrin-containing composition for preventing surgical adhesions - A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin. | 2010-09-23 |
20100240608 | PARTICLE STABILISED OIL-IN-WATER EMULSION - The present invention relates to an oil-in-water emulsion comprising a gelled particle emulsifier derived from naturally occurring food-grade polymers, the emulsion preferably being in the form of a food product or a home care product or a personal care product or a pharmaceutical product. | 2010-09-23 |
20100240609 | PHTHALOCYANINE SALT FORMULATIONS - Pharmaceutical compositions of phthalocyanine compounds with a structure according to Formula (I) are described. Phthalocyanines are photosensitizer compounds having a phthalocyanine ring system that can be used for photodynamic therapy. Different phthalocyanines and phthalocyanine salts are shown to have useful characteristics such as water solubility, oil solubility, or tunable photostability. Formulations of phthalocyanines and phthalocyanine salts that can be used for topical and systemic administration are described. | 2010-09-23 |
20100240610 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF - This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one quinolone based compound. This invention further involves assays for the detection of a hydroxyproline residue in a HIF molecule. | 2010-09-23 |
20100240611 | METHODS FOR PREPARING DPP-IV INHIBITOR COMPOUNDS - Methods for preparing an inhibitor of dipeptidyl peptidase IV, as well as formulations of such inhibitors of dipeptidyl peptidase IV that have a high degree of stability including under warm, humid storage conditions. | 2010-09-23 |
20100240612 | Prenylated Bisphosphonates as Anti-tuberculosis Agents - The invention provides methods to treat a mycobacterium infection and methods to inhibit mycobacterial polyprenyl pyrophosphate synthesis with a compound of formula I. The invention also provides novel compounds of formula I as well as salts and prodrugs thereof. | 2010-09-23 |
20100240613 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF - The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I] | 2010-09-23 |
20100240614 | Indole Compounds Bearing Aryl or Heteroaryl Groups Having Sphingosine 1-Phosphate (S1P) Receptor Biological Activity - The invention provides well-defined aryl and/or heteroaryl substituted indoles that are useful as spingosine-1-phosphate agonists or antagonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors. | 2010-09-23 |
20100240615 | NITRIC OXIDE DONORS - The invention relates to novel NO donors which are targeted to the mitochondria. The NO donor compounds of the invention allow NO to be selectively provided to the mitochondria. | 2010-09-23 |
20100240616 | NOVEL LIPID COMPOUNDS - Omega-3 lipid compounds of the general formula (I): | 2010-09-23 |
20100240617 | BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 2010-09-23 |
20100240618 | SUBSTITUTED PIPERAZINES - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists. | 2010-09-23 |
20100240619 | FUNGICIDAL MIXTURES - Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1 N-oxides, and salts thereof, | 2010-09-23 |
20100240620 | 3-Cyano-5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases - The present application relates to novel aryl-substituted 3-cyano-5-thiazolyl- and 3-cyano-5-thiadiazolyl-1,4-dihydropyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders. | 2010-09-23 |
20100240621 | TOPICAL PHARMACEUTICAL COMPOSITION FOR THE COMBINATION OF FUSIDIC ACID AND A CORTICOSTEROID - The present invention relates to topical pharmaceutical compositions comprising fusidic acid and a corticosteroid. More particularly, the present invention relates to topical pharmaceutical compositions comprising fusidic acid and mometasone or halobetasol or their esters, processes for preparing the same, and the use of such compositions for prevention and treatment of dermal infections. | 2010-09-23 |
20100240622 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention provides compositions and kits comprising at least one nitric oxide enhancing prostaglandin compound or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating ophthalmic disorders; (b) treating cerebrovascular disorders; (c) treating cardiovascular disorders; (d) treating benign prostatic hyperplasia (BPH); (e) treating peptic ulcers; (e) treating sexual dysfunctions and (f) inducing abortions. The nitric oxide enhancing prostaglandin compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. | 2010-09-23 |
20100240623 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 - The present invention provides 8-oxoadenine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The 8-oxoadenine derivatives act as modulators of Toll-like Receptor (TLR) 7 and thus may be used in the treatment of asthma, hepatitis, allergic diseases, viral and bacterial infection as well as cancer. | 2010-09-23 |
20100240624 | Ophthalmic Formulations of Ketotifen and Methods of Use - The present invention provides topical formulations of ketotifen that provide a comfortable formulation when instilled in the eye and are effective in the treatment and prevention of ocular allergy, particularly allergic conjunctivitis. The invention further provides methods of treating and preventing ocular allergy by in a subject in need of such treatment by topical application of the ketotifen formulations of the invention to the eye of a subject in need thereof. | 2010-09-23 |
20100240625 | Ophthalmic Formulations of Cetirizine and Methods of Use - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye. | 2010-09-23 |
20100240626 | ANTIEMETIC-ORAL CONTRACEPTIVE COMBINATION - The present invention relates to a method of reducing the incidence of nausea and vomiting associated with the administration of oral contraceptive formulation and a method of preparation of oral contraceptive formulation comprising progestin and/or estrogen and an antiemetic. The preferred oral contraceptive formulation comprises of levonorgestrel and an antiemetic. | 2010-09-23 |
20100240627 | COMPOSITION AND METHODS RELATING TO GLUCOCORTICOID RECEPTOR-ALPHA AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS - Methods of treating a glucocorticoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering, in combination, a glucocorticoid receptor agonist and a PPAR agonist in therapeutically effective amounts. It is an aspect of the present invention that the amount of the glucocorticoid receptor agonist used in a method of treating a glucocorticoid-responsive condition is less than an amount of the glucocorticoid receptor agonist necessary to achieve a therapeutic effect if administered in the absence of the PPAR agonist. | 2010-09-23 |
20100240628 | SKIN TREATMENTS - Compositions comprising an LXR activator and retinoic acid and/or a metabolic precursor thereto are useful in reducing the effects of chronoageing and/or photoageing of the skin. | 2010-09-23 |
20100240629 | POLYMORPHS OF FLUTICASONE FUROATE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides crystalline forms of Fluticasone furoate, characterized by the data disclosed in the specification; pharmaceutical compositions comprising any one or combination of the crystalline forms of Fluticasone furoate and at least one pharmaceutically acceptable excipient; and the use of the crystalline forms of Fluticasone furoate in the preparation of pharmaceutical formulations. | 2010-09-23 |
20100240630 | COMPOUNDS AND THERAPEUTIC USES THEREOF - The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. | 2010-09-23 |
20100240631 | PHARMACEUTICAL COMPOSITION FOR THE SUBLINGUAL ADMINISTRATION OF PROGESTERONE, AND METHOD FOR ITS PREPARATION - A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described. | 2010-09-23 |
20100240632 | DRUG FOR IMPROVING HYPERGLYCEMIA - A compound having a hyperglycemia improving effect and a hemoglobin A1c lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia. | 2010-09-23 |
20100240633 | Cancer treatment methods - The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications. | 2010-09-23 |
20100240634 | Fluorene Compound and Pharmaceutical Use Thereof - The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: | 2010-09-23 |
20100240635 | Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 2010-09-23 |
20100240636 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS - The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compounds. The compounds are useful as PPARγ agonist, through activating PPAR-RXR heterodimers that intereacts with specific DNA response elements within promoter regions of target gene, particularly in the treatment and prevention of polycystic kidney and cancer. | 2010-09-23 |
20100240637 | Inhibitors of the Interaction Between MDM2 and P53 - The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds: | 2010-09-23 |
20100240638 | Organic Compounds and their uses - The present application describes macrocyclic compounds of formula (I) with NS3 protease inhibitory activity for treating hepatitis C virus infection. | 2010-09-23 |
20100240639 | Sulfonyl-Derivatives as Novel or Histone Deacetylase - This invention comprises the novel compounds of formula (I) | 2010-09-23 |
20100240640 | (THIO) Carbamoyl-Cyclohexane Derivatives as D3/D2 Receptor Antagonists - The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): | 2010-09-23 |
20100240641 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors - The present invention provides a compound of formula I: | 2010-09-23 |
20100240642 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators - The present invention relates to certain indole derivatives that are modulators of PPARγ, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. | 2010-09-23 |
20100240643 | Use of Active Substance Combinations Having Insecticidal Properties for Controlling Animal Pests from the Stink Bug Family - The present invention relates to the use of active substance combinations which consist firstly of known cyclic ketoenols and secondly of further known insecticidal active substances, for controlling animal pests from the stink bug family (Pentatomidae). | 2010-09-23 |
20100240644 | MORPHOLINE DERIVATIVE - The present invention provides a morpholine derivative of the formula [I]; | 2010-09-23 |
20100240645 | COMBINATION OF CHECKPONIT KINASE (CHK) AND TELANGIECTASIA MUTATED (ATM) INHIBITORS FOR THE TREATMENT OF CANCER - A combination, comprising a checkpoint kinase (CHK) inhibitor, or a pharmaceutically acceptable salt thereof, and an ataxia telangiectasia mutated (ATM) inhibitor, or a pharmaceutically acceptable salt thereof is described. | 2010-09-23 |
20100240646 | PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS - Compounds having the formula (I), | 2010-09-23 |
20100240647 | Treatment of Alzheimer's Disease and Related Conditions - Compounds of formula (I) inhibit microtubule affinity regulating kinase (MARK), and hence are suitable for treating diseases associated with abnormal phosphorylation of tau. | 2010-09-23 |
20100240648 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS - Certain hexahydro-pyrrolo-isoquinoline compounds are histamine H | 2010-09-23 |
20100240649 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS - A compound of formula (I), | 2010-09-23 |
20100240650 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS - The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder. | 2010-09-23 |
20100240651 | WATER-SOLUBLE THALIDOMIDE DERIVATIVES - A compound of formula (I), | 2010-09-23 |
20100240652 | Pyridine Derivatives as Sodium Channel Modulators - The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain. | 2010-09-23 |
20100240653 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to certain biphenyl sulfonamide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3-receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as, cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such as narcolepsy, shift-work syndrome, drowsiness as a side effect from a medication, maintenance of vigilance to aid in completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease and the like. | 2010-09-23 |
20100240654 | HYDRAZIDE DERIVATIVES - A compound represented by the following general formula (1) or a salt thereof or a hydrate of the foregoing is safe while exhibiting suitable physicochemical stability, and is useful as therapeutic or prophylactic agents for diseases associated with thrombus formation. | 2010-09-23 |
20100240655 | BROMO-PHENYL SUBSTITUTED THIAZOLYL DIHYDROPYRIMIDINES - Bromo-phenyl substituted thiazolyl dihydropyrimidines and combinations thereof with other antiviral agents for combating HBV infections. | 2010-09-23 |
20100240656 | COMPOUNDS AS HSP90 INHIBITORS - The invention provides novel compounds of formula (I) wherein: one of the a, b, c or d members is a nitrogen atom and the remaining members are carbon atoms; and R | 2010-09-23 |
20100240657 | CHEMICAL COMPOUNDS - The present invention encompasses compounds of general formula (1) wherein the groups R | 2010-09-23 |
20100240658 | Oxadiazole Derivatives - The invention relates to compounds of formula I: | 2010-09-23 |
20100240659 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY - Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. | 2010-09-23 |
20100240660 | NEW HISTONE DEACETYLASES INHIBITORS - New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) | 2010-09-23 |
20100240661 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS - The present invention relates to novel compounds of formula (I) or a salt thereof: | 2010-09-23 |
20100240662 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO - Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis. | 2010-09-23 |